Literature DB >> 29790187

Eosinophilic annular erythema treated with dupilumab.

Samantha C Gordon1, Sarah N Robinson2, Minawaer Abudu1, Michelle Her1, Sandyha Deverapalli1, Adrianne Levin1, Birgitta A R Schmidt3, Stephen E Gellis4, David Rosmarin1.   

Abstract

Eosinophilic annular erythema is a rare, benign, recurrent condition characterized by annular skin lesions, tissue eosinophilia, and resistance to a variety of treatments. There are fewer than 30 cases reported in the English literature, 7 of which are in children. We present a case of recurrent eosinophilic annular erythema in an adolescent that was successfully treated with dupilumab, an interleukin-4 receptor alpha antagonist.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  pharmacology; therapy-systemic; urticaria

Mesh：

Substances：

Year:  2018        PMID： 29790187     DOI： 10.1111/pde.13533

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN： 0736-8046            Impact factor:   1.588


  4 in total

Review 1.  An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics.

Authors:  Roberto Bernardini; Gaia Toschi Vespasiani; Arianna Giannetti
Journal:  Medicina (Kaunas)       Date:  2022-04-29       Impact factor: 2.948

Review 2.  Learning From Success and Failure: Biologics for Non-approved Skin Diseases.

Authors:  Reinhart Speeckaert; Jo Lambert; Nanja van Geel
Journal:  Front Immunol       Date:  2019-08-08       Impact factor: 7.561

3.  [Eosinophilic annular erythema in a 20-month-old girl].

Authors:  Verena Paulitschke; Julia Tittes; Adrian Tanew; Sonja Radakovic
Journal:  Hautarzt       Date:  2021-04       Impact factor: 0.751

4.  Can't handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab.

Authors:  Eva Shelton; Coley Doolittle; Michi M Shinohara; John A Thompson; Ata S Moshiri
Journal:  JAAD Case Rep       Date:  2022-02-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.